Cognivia is an innovator of analytical tools to optimize and accelerate the clinical development of new medicines. The privately held company was founded in 2013 by longtime colleagues with decades of experience in the pharmaceutical industry who set out to tackle some of the most challenging issues that prevent drugs from reaching the marketplace. Cognivia helps lessen risk and helps increase clinical trial success. It can help reduce the variability of study data by 30 percent. This can lead to fewer patients needed in a study, equating to less cost and time.
The company offers Placebell©™, a solution that improved clinical trial assay sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies.
The company offers Placebell©™, a solution that improved clinical trial assay sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies.
Location: Belgium, Walloon Brabant, Mont-Saint-Guibert
Employees: 11-50
Total raised: $16.47M
Founded date: 2013
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.04.2024 | - | $16.47M | - |
Mentions in press and media 8
| Date | Title | Description |
| 11.11.2024 | Navigating FDA's Diversity Action Plan Draft Guidance: From Strategic Planning Through Study Success, Upcoming Webinar Hosted by Xtalks | www.cognivia.com In this free webinar, learn about the critical importance of a coherent and comprehensive diversity action plan-integrated approach. Gain valuable insights from industry and academic leaders on mitigating implementation cha... |
| 18.04.2024 | Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions | Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research t... |
| 18.04.2024 | Cognivia Secures Strategic €15.5M Funding | Cognivia, a Mont-Saint-Guibert, Belgium-based AI company dedicated to innovating pharmaceutical and biotech clinical research, raised €15.5M in funding. Backers included Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d... |
| 18.04.2024 | Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions | Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research t... |
| 10.04.2024 | Navigate Placebo Response: Insights and Mitigation Strategies for Clinical Excellence, Upcoming Webinar Hosted by Xtalks | www.cognivia.com In this free webinar, discover the key ideas to mastering placebo responses in clinical trials in 2024 and beyond. Attendees will learn about the latest biological insights and pragmatic mitigation strategies for trial succ... |
| 07.06.2023 | Predicting Non-Adherence and Dropout Risks: Enhance Clinical Trial Efficiency and Support Patient Engagement, Upcoming Webinar Hosted by Xtalks | It has been common practice to compensate for patient dropouts by recruiting extra sites and patients, and depending on the therapeutic focus, this may result in 20-30 percent more patients and costs. TORONTO (PRWEB) June 07, 2023 Poor pati... |
| 06.06.2023 | Patient Adherence and Engagement: Predicting Non-Adherence and Dropout Risks, Upcoming Webinar Hosted by Xtalks | It has been common practice to compensate for patient dropouts by recruiting extra sites and patients, and depending on the therapeutic focus, this may result in 20-30 percent more patients and costs. TORONTO (PRWEB) June 06, 2023 Poor pati... |
| 23.05.2023 | Cognivia Expands Its Portfolio of Predictive Solutions Introducing Compl-AI, an Innovative Solution That Predicts the Risk of Patient Nonadherence & Dropout | Cognivia, a clinical trial technology company that combines machine learning with a sophisticated evaluation of patient characteristics and traits, is proud to announce the launch of its latest innovation: Compl-AI. Compl-AI is a predictive... |